In-license from a French biotechnology company on the autogenous myoblast transplantation for urinary incontinence thearapy

SCSKK signed a license agreement with Celogos, a French biotechnology company of technologies for myoblast cell implantation for the treatment of stress urinary incontinence on an exclusive basis in Japan under the patent and know-how agreement.
PDF file
LastUpdate : 2007-02-15 17:00